Perceived experiences of people with severe haemophilia A switching from factor VIII prophylaxis to emicizumab
Open Access
- 1 January 2025
- journal article
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 87-95
Abstract
Introduction: Emicizumab is a humanised, bispecific monoclonal antibody that bridges activated factor (F) IX and FX; it is approved for treatment of people with haemophilia A (PwHA) of all ages, with or without FVIII inhibitors. Qualitative experiences of PwHA switching to non-factor treatments, such as emicizumab, are needed to facilitate shared decision-making (SDM). Aim: This study aimed to describe experiences of switching from FVIII prophylaxis to emicizumab among PwHA. Methods: Participants with severe haemophilia A without FVIII inhibitors from the Swedish cohort of the HemiNorth 2 study (MO42245; EudraCT# 2020-003256-32) were subject to qualitative interviews in 2023, which were analysed through content analysis. Results: Overall, nine participants were interviewed. The analysis revealed three categories: ‘Adapting to a new reality’, ‘A feeling of normality’ and ‘Shattered expectations’. Participants reported that switching from FVIII prophylaxis to emicizumab fostered a feeling of normality, with the disease taking less time and space in their daily lives. The participants also described increased confidence in physical activity, and a newfound hope for the future treatment of haemophilia. However, not all expectations were met, as the disease persisted and still affected daily life. Some participants also reported a lack of information about emicizumab from a patient perspective. Conclusion: The findings convey a sense of normality among PwHA switching to emicizumab, stemming from a reduced disease and treatment burden. The results highlight the gaps in knowledge among PwHA, which can help inform SDM practice and manage expectations when switching to a non-factor treatment.Keywords
This publication has 41 references indexed in Scilit:
- Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit InterviewsClinical Therapeutics, 2024
- Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyThe Lancet Haematology, 2023
- Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspectiveCritical Reviews in Oncology/Hematology, 2022
- Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)Research and Practice in Thrombosis and Haemostasis, 2022
- Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative StudyThe Patient - Patient-Centered Outcomes Research, 2019
- Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnairesHematology, Transfusion and Cell Therapy, 2019
- Emicizumab: A Review in Haemophilia ADrugs, 2019
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsNew England Journal of Medicine, 2018
- Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18–30 years) with hemophiliaAmerican Journal of Hematology, 2015
- Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthinessNurse Education Today, 2004